Table 1. Main characteristics of the eligible studies.
| Study | Location | Subgroup | Regimen | Number of patients | Male | Female | Age (Mean) | MMSE (Mean±SD) | ADAS-cog (Mean±SD) | CIBIC-Plus (Mean±SD) |
|---|---|---|---|---|---|---|---|---|---|---|
| Black 2003 | UK | VD | Placebo | 199 | 115 | 84 | 74.2 | 21.7±0.3 | 20.1±0.7 | |
| Donepezil 5mg/day | 198 | 111 | 87 | 73.7 | 21.9±0.3 | 21.2±0.8 | ||||
| Donepezil 10mg/day | 206 | 107 | 99 | 73.9 | 21.8±0.3 | 20.9±0.7 | ||||
| Chang 2011 | Korea | PSCI | Placebo | 4 | 2 | 2 | 55 (28–74) | 24.8 (24–26) | ||
| Donepezil | 6 | 4 | 2 | 55.5 (45–69) | 24.2 (23–36) | |||||
| Moretti 2008 | Italy | PSCI | Rivastigmine | 50 | 19 | 31 | 74.23 | 18.6±2.1 | ||
| VD | Rivastigmine | 50 | 24 | 26 | 73.23 | 20.7±2.0 | ||||
| Narasimhalu 2010 | Singapore | PSCI | Placebo | 25 | 12 | 13 | 69.4 (48–84) | 23.9±3.2 | 30.4±14.1 | |
| Rivastigmine | 25 | 5 | 20 | 68.1 (57–81) | 23.7±3.4 | 29.9±13.1 | ||||
| Pratt 2002 | Various | VD | Placebo | 392 | 220 | 172 | 74.3 (41–91) | 21.6±4.2 | 22.3±11.1 | |
| Roman GC 2010 | US | VD | Placebo | 326 | 176 | 150 | 72.3 | 23.6±0.3 | 21.7±0.6 | 3.6±0.05 |
| Donepezil | 648 | 398 | 250 | 73.4 | 23.5±0.2 | 21.8±0.4 | 3.6±0.03 | |||
| Wilkinson 2003 | Various | VD | Placebo | 193 | 105 | 88 | 74.4 | 22.2±0.3 | 18.8±0.7 | |
| Donepezil 5mg/day | 208 | 130 | 78 | 74.7 | 21.8±0.3 | 20.8±0.7 | ||||
| Donepezil 10mg/day | 2115 | 134 | 81 | 75.7 | 21.5±0.3 | 20.6±0.7 |
Numbers in parentheses represent percentage
Abbreviations: MMSE, mini–mental state examination; ADAS-cog, Alzheimer’s Disease Assessment Scale-Cognitive subscale; CIBIC-Plus, Clinician’s Interview-Based Impression of Change-Plus; UK, United Kingdom; VD, vascular dementia; PSCI, post-stroke cognitive impairment; US, United States